What happened there? Hearing from other users of several assay issues, a recall, difficulty of getting through to their hotliners, rumours of being for sale?
The analogue is the Irish farmer who used to take his produce to market on his donkey. Times got hard, margins got thinner so he fed the donkey less hay to keep his margins. Worked for a while then margins got thinner so he fed the donkey even less hay. This too worked for a while.
Then the donkey died.
Buy shares in a dead donkey? Probably not.
No new assays? There's a surprise. The UK immunoassay development team was culled ages ago and probably work in other fields now. I did.
Scary thing is that O-CD is not an isolated example. The whole of the diagnostics business seems to be using the wrong slash and burn model.
very sad as this was once an organization with great promise
they had innovative technology (dry slide and enhanced chemi-luminesence), decent equipment with friendly software, and great service
then I saw, as a customer, J&J begin a constant cost cutting approach. Field service was slowly degraded with longer and longer response times, user groups in our area became a thing of the past, rapid change over is sales management. Promises of 'new assay's' yet that takes investment. Our ESR was very good.
now we are dealing with sodium and triglyceride issues, phenobarbitol recall, have to go to a different vendor for micro albumin
all with seemingly few answers
In my opinion it seems to me that there is a real lack of 'clinical lab' people in their decision making area.
A spin-off to shareholders?
Well, I am an ex O-CD-er and a J&J shareholder and pensioner. I certainly would not want O-CD shares spun in my direction.
Too late to mend it.
Had not heard much about their situation as they are such minor players now. But it explains why last week on site one of their engineers asked me if any jobs available with us, followed by the same question from the Beckman engineer 10 minutes later. As if things are any better elsewhere.
Management speak for we are going to close you down.
J&J are evaluating options for O-CD. These include a possible divestiture, a spin-off to shareholders, a strategic alliance, or keeping O-CD within J&J.
O-CD got rid of its UK R&D, which developed the assays and was the World's leading enhanced chem-luminescence immuno-assay group, 13 years ago.
Manufacture, still in Wales, is thus technically unsupported. I don't count Raritan as 'support'.
I am amazed the ECi system is still on the market. The competition must be really crap.
O-CD for sale? Who would buy? May be some tire-kicking but that's it.
which assys are they having trouble with? what assays were recalled?
More information about formatting options